Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | CASP1 | P29466 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23980 | 0.76 | MAPT (0.55) | MAPTKDM4EALDH1A1NPC1POLB | |
| SCHEMBL3934900 | 0.71 | — | — | |
| SCHEMBL18594 | 0.70 | ALDH1A1 (0.44) | MAPTKDM4EALDH1A1NPC1POLB | |
| SCHEMBL16317 | 0.68 | KDM4A (0.32) | — | |
| SCHEMBL23226 | 0.67 | CCR1 (0.48) | MAPTKDM4EALDH1A1NPC1CYP3A4 | |
| SCHEMBL17511979 | 0.67 | CYP3A4 (0.49) | MAPTKDM4EALDH1A1NPC1POLB | |
| SCHEMBL9436 | 0.67 | EGFR (0.37) | CYP2A6 | |
| SCHEMBL3936319 | 0.67 | — | — | |
| SCHEMBL276736 | 0.67 | KDM4E (0.38) | MAPTKDM4EALDH1A1CYP2A6NPC1 | |
| SCHEMBL450508 | 0.67 | MAPT (0.38) | MAPTKDM4EALDH1A1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | claimed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | claimed |
| CN-113473971-B | Pharmaceutical formulations | 詹森药业有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | disclosed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-09 | — | — | US | disclosed |
| EP-3927324-A1 | PHARMACEUTICAL FORMULATIONS | Janssen Pharmaceutica NV (BE) | 2021-12-29 | — | — | EP | disclosed |
| CN-113473971-A | Pharmaceutical formulations | 詹森药业有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005080368-A2 | BENZOPYRAN COMPOUND USEFUL FOR THE TREATMENT OF ARRHYTMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-01 | — | — | WO | disclosed |
| EP-1549618-A1 | PYRAZOLONE COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004033433-A1 | PYRAZOLONE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-22 | — | — | WO | disclosed |
| US-5280009-A | Herbicide | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-18 | — | — | US | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | MAPT 2314/4885KDM4E 3526/4885ALDH1A1 2543/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | MAPT 3183/4885KDM4E 3898/4885ALDH1A1 3610/4885 |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | MALT1, MGAM, MGLL | MAPT 887/4885KDM4E 1704/4885ALDH1A1 2560/4885 |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | TREH, F12, CEL | MAPT 62/4885KDM4E 2572/4885ALDH1A1 2990/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | MAPT 2314/4885KDM4E 3526/4885ALDH1A1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.